Cancer Discov. 2019 Jan;9(1):OF4. doi: 10.1158/2159-8290.CD-NB2018-156. Epub 2018 Nov 27.
Entrectinib may be an effective therapy for patients with fusion-positive solid tumors, regardless of tumor type. In a combined analysis of phase I and phase II trials, more than half of patients responded to the drug, with a similar response rate in patients whose cancer had spread to the brain.
恩曲替尼可能是一种对融合阳性实体瘤患者有效的疗法，无论肿瘤类型如何。在一项I期和II期试验的联合分析中，超过一半的患者对该药物有反应，癌症已扩散至脑部的患者的反应率与之相似。
